MedPage Today brought together three expert leaders for a virtual roundtable discussion on the joint meeting of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) and ...
Mapi Pharma Ltd., a fully integrated, late-stage clinical development biopharmaceutical company focused on introducing innovative long-acting depot injectable treatments, will present efficacy data ...
The over‐the‐counter supplement lipoic acid may have a small beneficial effect in slowing the loss of gray matter in the brains of people with progressive forms of multiple sclerosis, according to new ...
Throughout the course of multiple sclerosis, gradually progressive neurologic impairment can occur, which has been called disability accrual. Current disease-modifying therapies for multiple sclerosis ...
Living with a chronic, progressive condition such as secondary progressive multiple sclerosis (SPMS) can affect both your physical and mental health. SPMS results in a gradual decline in function over ...
- Patients on fenebrutinib had low relapse rates with data showing no active brain lesions or disability progression after nearly two years of treatment - - Phase III studies for fenebrutinib in ...
Latest News and Articles on Multiple sclerosis. Read stories and expert opinion articles on Multiple sclerosis at ...
New evidence added to the literature that paramagnetic rim lesions (PRLs) may be a biomarker of disability accumulation in multiple sclerosis (MS). PRLs are thought to capture a subset of chronic ...
Constipation having bowel movements less often than usual or stools that are hard or difficult to pass can affect how you feel throughout your day, disrupt routines, and make other multiple sclerosis ...
A new University of Toronto-led study has discovered a possible biomarker linked to multiple sclerosis (MS) disease progression that could help identify patients most likely to benefit from new drugs.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results